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Abstract
Diabetes mellitus is a metabolic disease characterised 
by chronically high glucose levels. Genetic factors have 
been implicated in the aetiology following mutations in 
a single gene. An extremely rare form of  diabetes mel-
litus is monogenic diabetes, a subset of  which is per-
manent neonatal diabetes, and is usually suspected if  a 
child is diagnosed with diabetes at less than 6 months 
of  age.
We present the first case reported from East Africa of  
a child diagnosed with permanent neonatal diabetes re-
sulting from a mutation in the KCNJ11 gene encoding 
the Kir6.2 subunit.
Despite the rarity of  permanent neonatal diabetes, this 
diagnosis should be considered in infants with persis-
tent hyperglycaemia requiring insulin therapy. Children 
with an ATP-sensitive potassium channel defect in the 
pancreatic beta cell have an overall good prognosis 
when treated with oral sulphonylurea therapy. 
Background
Diabetes mellitus is a metabolic disease characterized 
by chronically high glucose levels and can present at any 
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age from birth1. Genetic factors have an important role 
in the pathogenesis of  diabetes and indeed some forms 
of  diabetes mellitus are as a result of  a mutation in a 
single gene1-5. 
Monogenic diabetes presenting in infancy may be di-
vided into transient and permanent neonatal diabetes. 
Both present with hyperglycaemia in infancy however 
in the former the patient may resolve spontaneously at 
3 months with no more insulin requirement until later 
in life when the disease may relapse. In the latter, insulin 
supplementation is required for life in the majority of  
cases.4,6 
The two commonest forms of  neonatal diabetes de-
scribed are the imprinted anomalies of  the 6q24 locus 
involving the ZAC and HYAMI genes (producing tran-
sient neonatal diabetes) and the KCNJ11 gene encod-
ing the Kir6.2 subunit of  the  ATP sensitive potassi-
um channel (producing permanent neonatal diabetes). 
Other gene mutations leading to permanent neonatal 
diabetes include ABCC8 gene mutation involving the 
SURI subunit of  the ATP sensitive potassium channel 
and INS (insulin) gene mutation.
Making a specific genetic diagnosis is important since it 
has implications on the type of  treatment that should 
be given, thus improving prognosis. This has particu-
larly been seen with permanent neonatal diabetes sec-
ondary to a mutation in the KCNJ11 gene encoding the 
Kir6.2 subunit where good glycaemic control has been 
achieved with oral sulphonylureas.7,8. 
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Case report
ME was delivered at term by emergency caesarean sec-
tion following foetal distress. He was a small for ges-
tational age baby with a birth weight of  2,300 grams. 
He then went through a series of  hospital visits and 
admissions for probable neonatal sepsis. 
At 6 weeks of  age he presented in DKA (Diabetic ke-
toacidosis) with a random blood glucose level of  Hi 
(NR-72-200mg/dl) and pH of  6.9 (NR;7.35-7.45) on 
an arterial blood gas analysis. A septic workup excluded 
an infectious aetiology. 
At discharge, fairly good glycaemic control was achieved 
with a combination of  short acting and intermediate act-
ing insulin. This regimen was maintained for 18 months 
during which time his average HbA1c was 10.6%. His 
growth and development progressed normally during 
this time only complicated by two admissions for recur-
rence of  diabetic ketoacidosis. 
Blood samples of  the parents and ME where taken 
off  for genetic testing. Mutation analysis of  KCNJ11, 
ABCC8 and INS genes was undertaken. A missense 
mutation, p.R201C, on KCNJ11 gene on the Kir6.2 
subunit encoding for beta cell ATP-sensitive potassium 
channel was confirmed with ME. Both his parents were 
found to be normal. ME was gradually transitioned 
from insulin to an oral suphonylurea (glibenclamide). 
His C-peptide assays were <0.05ng/ml (NR-0.8-3.1ng/
ml) before initiating glibenclamide tablets and improved 
to 1.39ng/ml two months after the change in treatment. 
He is presently 3.5 years with a weight of  16 kgs and 
height of  122 cms. He has an HbA1c of  4.1%. His oral 
glibenclamide dose was initially at 1.6mg/kg/day but 
has been reduced to 0.9mg/kg/day with good glycae-
mic control, with the tablets being given twice a day.  
Discussion
Monogenic diabetes is an extremely rare condition 
worldwide, representing 1-2% of  all paediatric diabe-
tes1. A database search does not reveal many African 
cases of  neonatal diabetes with one other case report-
ed from Morocco9 and a few others from the southern 
part of  Africa. This could be due to the very low index 
of  suspicion, the rarity of  the condition and the diffi-
culty in accessing the tests needed to confirm it.
Majority of  infants with permanent neonatal diabetes 
tend to have a low birth weight that is at the 3rd centile 
or lower3,10,11 and many present with associated ketoaci-
dosis. This was the same presentation for ME who was 
a low birth weight baby and was also diagnosed with 
diabetes following presentation at 6 weeks of  age with 
ketoacidosis. The low birth weight of  most of  these 
babies is due to impaired insulin secretion during the 
intrauterine period. It is also believed that residual insu-
lin allows the body to continue functioning almost nor-
mally for a few weeks after birth before the diagnosis3.  
A molecular aetiology can be confirmed in most pa-
tients by molecular DNA testing3,5,7,12. These tests are 
expensive and not readily accessible in Africa, however 
some centers outside Africa offer them, at no cost, for 
research purposes.
The mutation(s) associated with permanent neonatal 
diabetes mellitus may be dominantly or recessively in-
herited or may occur as a de novo mutation giving rise 
to a new case.7 ME had a genetic mutation identified 
but both his parents had the same genetic testing and 
were found to be normal, indicating that this was most 
likely a sporadic mutation. Most of  the mutations seen 
in monogenic diabetes affect the functioning of  the in-
sulin producing pancreatic beta cells.1,4,7,10,12
The mutation identified was p.R201C on KCNJ11 gene 
on the Kir6.2 subunit encoding for beta cell ATP-sensi-
tive potassium channel.
This mutation on the KCNJ11 gene causes diabetes by 
diminishing the responsiveness of  the channel to in-
creased ATP and reduced ADP concentrations. This al-
tered sensitivity of  the channel to the ATP: ADP ratio 
results in increased potassium efflux from the cell and 
cell membrane hyperpolarization results, thus reducing 
insulin secretion from the beta-cell.4,12
Transitioning ME from insulin to sulphonylureas was 
found to improve his glycaemic control as evidenced by 
the improvement of  his HbA1c. This is similar to other 
patients with the same genetic mutation.4,7,8 Although 
the doses of  sulphonylureas required may be higher 
than those of  adults on sulphonlyureas, few side effects 
have been reported and some patients have been able 
to reduce the dose with still good glycaemic control.7,8
There is good evidence to suggest that diabetes diag-
nosed in the first 6 months of  life is not Type 1 diabetes 
mellitus since autoantibodies are rarely present7,11. The 
presence of  insulin differentiates this condition from 
Type 1 diabetes where there may be total absence of  
insulin after the ‘honeymoon’ period.7 Exogenous in-
sulin suppresses the production of  insulin in a patient 
with KCNJ11 gene mutation on insulin therapy. How-
ever, when it is discontinued and an oral sulphonylurea 
is initiated, the body begins to produce insulin and a 
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by-product from the metabolism of  insulin, C-pep-
tide, is released. This was evident in ME following the 
change in therapy. 
Catch up growth is known to occur in these children 
once the insulin deficiency is corrected and most of  
them grow along the same growth centiles as other 
non-diabetic children with an overall good progno-
sis7,8,10. The exceptions to this are a certain minority 
of  children with a different type of  mutation on the 
KCNJ11 gene. These patients may have associated neu-
rological disease characterized by developmental delay, 
muscle weakness, seizures and dysmorphic features6,7.
Conclusion
Neonatal diabetes is known to be a rare condition 
worldwide but should be suspected in low birth weight 
infants with persistent hyperglycaemia requiring insulin 
therapy. A genetic cause can be identified in most of  
these cases, affecting the choice of  treatment. 
Most of  the children with a KCNJ11 gene mutation 
affecting the ATP-sensitive potassium channel in the 
pancreatic beta cell have an overall good prognosis with 
good glycaemic control attained with oral sulphony-
lurea therapy.
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